ArticleThe Journal of infectious diseases2015
A Kunjin Replicon Virus-like Particle Vaccine Provides Protection Against Ebola Virus Infection in Nonhuman Primates.
Article in The Journal of infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 45 citations in OpenAlex.
- Replicon RNA vaccines: design, delivery, and immunogenicity in infectious diseases and cancer.Journal of hematology & oncology · 2025Review
- Tracing down the updates on Ebola virus surges: An update on anti-ebola therapeutic strategies.Journal of translational internal medicine · 2023Article
- mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV.Frontiers in immunology · 2023Review
- Replication-Deficient Zika Vector-Based Vaccine Provides Maternal and Fetal Protection in Mouse Model.Microbiology spectrum · 2022Article
- The Delivery of mRNA Vaccines for Therapeutics.Life (Basel, Switzerland) · 2022Review
- Article
- Self-Replicating RNA Viruses for Vaccine Development against Infectious Diseases and Cancer.Vaccines · 2021Review
- Development of a Multivalent Kunjin Virus Reporter Virus-Like Particle System Inducing Seroconversion for Ebola and West Nile Virus Proteins in Mice.Microorganisms · 2020Article
- Application of Viral Vectors for Vaccine Development with a Special Emphasis on COVID-19.Viruses · 2020Review
- Self-Amplifying RNA Viruses as RNA Vaccines.International journal of molecular sciences · 2020Review
- Immunogenicity of RNA Replicons Encoding HIV Env Immunogens Designed for Self-Assembly into Nanoparticles.Molecular therapy : the journal of the American Society of Gene Therapy · 2019Article
- Advances in mRNA Vaccines for Infectious Diseases.Frontiers in immunology · 2019Review
- Self-Replicating RNA Viruses for RNA Therapeutics.Molecules (Basel, Switzerland) · 2018Review
- Production of Ebola virus-like particles in Drosophila melanogaster Schneider 2 cells.Journal of virological methods · 2018Article
- Latest development on RNA-based drugs and vaccines.Future science OA · 2018Review
- Successful post-exposure prophylaxis of Ebola infected non-human primates using Ebola glycoprotein-specific equine IgG.Scientific reports · 2017Article
- Mosquito cell-derived West Nile virus replicon particles mimic arbovirus inoculum and have reduced spread in mice.PLoS neglected tropical diseases · 2017Article
- Ebola vaccines in clinical trial: The promising candidates.Human vaccines & immunotherapeutics · 2017Review
- Alphavirus Replicon DNA Vectors Expressing Ebola GP and VP40 Antigens Induce Humoral and Cellular Immune Responses in Mice.Frontiers in microbiology · 2017Article
- Replicon RNA Viral Vectors as Vaccines.Vaccines · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 3 countries.
Funding
Abstract
The current unprecedented outbreak of Ebola virus (EBOV) disease in West Africa has demonstrated the urgent need for a vaccine. Here, we describe the evaluation of an EBOV vaccine candidate based on Kunjin replicon virus-like particles (KUN VLPs) encoding EBOV glycoprotein with a D637L mutation (GP/D637L) in nonhuman primates. Four African green monkeys (Cercopithecus aethiops) were injected subcutaneously with a dose of 10(9) KUN VLPs per animal twice with an interval of 4 weeks, and animals were challenged 3 weeks later intramuscularly with 600 plaque-forming units of Zaire EBOV. Three animals were completely protected against EBOV challenge, while one vaccinated animal and the control animal died from infection. We suggest that KUN VLPs encoding GP/D637L represent a viable EBOV vaccine candidate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.